Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus (Albumin-Bound) in Advanced Solid Tumors
NCT05125523Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nab-sirolimus in solid tumor (advanced stage), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Number of participants with adverse events up to 3 years, Dose-Limiting Toxicities (Stage 1) and 3 more. Status: unknown.
02
Drugs
nab-sirolimus
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05125523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05125523.